Disclosure of grounds of European withdrawn and refused applications: a step forward on regulatory transparency.

The article discusses the process of evaluating new medicines in Europe conducted by regulatory authorities (RAs). It notes on the need for a greater transparency for medical regulations which has been advocated by public and scientific communities and is significant to understand the reasons on certain procedures for a successful or failed application. It indicates that the European Union (EU) has obliged the European Medicines Agency (EMA) to disclose information of drug applications.